Zhi-Tao Li

Zhi-Tao Li

Auto-generated profile, based on publicly available information

Zhi-Tao Li

Center for Disease Control and Prevention of Pudong New Area, Pudong Institute of Preventive Medicine, Fudan University, Shanghai, P.R. China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GWGuobin Wang
Guobin Wang
JNJianhua Niu
Jianhua Niu
ZLZhitao Li
Zhitao Li
HLHaifeng Lv
Haifeng Lv
HCHongliu Cai
Hongliu Cai
This study aimed to evaluate the efficacy and safety of dexmedetomidine versus any other treatment without dexmedetomidine in patients who have undergone cardiac surgery. Electronic databases including PubMed, Embase, and Cochrane Library were systematically searched without limitations of language and publication time. Randomized controlled trials (RCTs) aiming to evaluate the efficacy and safety of dexmedetomidine versus any other treatment without dexmedetomidine in patients that have undergone cardiac surgery were selected. Endpoints such as hemodynamic indexes and adverse events in eligible studies were extracted by two researchers, independently. The data was analyzed using RevMan 5.3 and Stata 11.0 software. A total of 18 RCTs met the inclusion criteria, involving 1730 patients. Compared to control (any treatment without dexmedetomidine), dexmedetomidine showed a pooled mean difference (MD) of -14.46 [95% confidence interval(CI): -24.69, -4.23; p<0.01] for systolic arterial pressure, a standardized mean difference (SMD) of -1.74 for mean arterial blood pressure (95% CI: -2.80, -0.68; P < 0.01), -2.12 (95%CI: -3.23, -1.00; p<0.01) for heart rate, and combined odds ratio (OR) of 0.22 (95%CI: 0.11, 0.44; p<0.01) for tachycardia, 3.44 (95%CI: 1.95, 5.96; p0.05) for atrial fibrillation, and 0.99 (95%CI: 0.51, 1.90; p>0.05) for hypotension. In addition, dexmedetomidine could reduce time of surgery and stay in intensive care units, improve delirium with good safety. Our study shows clinical application of dexmedetomidine in cardiac surgery patients can reduce risks of abnormal hemodynamics with good safety.

1 April 2015 in Microbial Pathogenesis
Verified
Journal Article
Closed access
ZLZhi-Tao Li
Zhi-Tao Li
RZRui-Ling Zhang
Rui-Ling Zhang
XBXiao-Gang Bi
Xiao-Gang Bi
LXLian Xu
Lian Xu
MFMin Fan
Min Fan
KZKou-Xing Zhang
Kou-Xing Zhang

8 June 2024 in iScience
Verified
Journal Article
Open access
JKJuzhong Ke
Juzhong Ke
XRXiaonan Ruan
Xiaonan Ruan
WLWenbin Liu
Wenbin Liu
XLXiaolin Liu
Xiaolin Liu
KWKang Wu
Kang Wu
GCGuangwen Cao
Guangwen Cao
The role of fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), and triglyceride-glucose index (TyG index) in predicting all-cause and cause-specific mortalities remains elusive. This study included 384,420 adults from the Shanghai cohort and the UK Biobank (UKB) cohort. After multivariable adjustment in the Cox models, FPG ≥7.0 mmol/L or HbA1c ≥ 6.5% increased the risk of all-cause mortality, FPG ≥5.6 mmol/L or HbA1c ≥ 6.5% increased CVD-related mortality, and higher or lower TyG index increased all-cause and CVD-related mortalities in the Shanghai cohort; FPG ≥5.6 mmol/L, HbA1c ≥ 5.7%, TyG index <8.31 or ≥9.08 increased the risks of all-cause, CVD-related, and cancer-related mortalities in the UKB cohort. FPG or HbA1c increased the discrimination of the conventional risk model in predicting all-cause and CVD-related mortalities in both cohorts. Thus, increased levels of FPG and HbA1c and U-shaped TyG index increase the risks of all-cause especially CVD-related mortalities.

14 January 2021 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
WWWei Wang
Wei Wang
ZLZhi-Tao Li
Zhi-Tao Li
NCNan-Nan Cui
Nan-Nan Cui
GWGuo-Bin Wang
Guo-Bin Wang
LMLiang Ma
Liang Ma
Background: Extranodal natural killer/T cell lymphoma (ENKL) is a rare subtype of non-Hodgkin lymphoma, and lung involvement is extremely rare. The patients with pulmonary ENKL always presented unspecific symptoms of the respiratory system, such as cough with sputum and varying degrees of fever, while developing into acute respiratory distress (ARDS) was seldomly reported, especially promoted by the surgical procedure. Case presentation: Here we describe a patient with nasal ENKL and most likely lung dissemination that was regarded as an infection at first. After nonresponse to a period of anti-infective therapy, this patient received surgical debridement. While the histopathology did not show the evidence of infection, but consistent with ENKL. The patient got refractory hypoxemia rapidly after surgery, with the LDH surging to a much higher level than before surgery. The ARDS was diagnosed, and he died on the 5th day after surgery. We postulate that ARDS was due to aggressive lymphoma proliferation promoted by the surgical procedure. Conclusions: Pulmonary ENKL developing into ARDS was scarce, and was likely attributed to the aggressive tumor cell proliferation after surgery in this case.